US2016287694A1PendingUtilityA1
Piscine reovirus immunogenic compositions
Est. expiryOct 2, 2029(~3.2 yrs left)· nominal 20-yr term from priority
A61P 31/12A61P 31/22A61P 31/14A61P 37/04A61K 31/7088C12N 2720/12234C12N 7/00C12N 2720/12022A61K 39/12A61K 2039/5252C12N 2720/12034A61K 2039/5254C07K 14/005A61K 2039/552G01N 33/5308A61K 39/15A61K 2039/70C12N 2720/12222C07K 16/10Y02A50/30
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus polypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal.
Claims
exact text as granted — not AI-modified1 .- 6 . (canceled)
7 . A Piscine Reovirus (PRV) immunogenic composition comprising a recombinant PRV polypeptide.
8 . The immunogenic composition of claim 7 , wherein the recombinant PRV polypeptide is a polypeptide encoded by a cDNA with the sequence of any of SEQ ID NOs: 1-10.
9 . (canceled)
10 . The immunogenic composition of claim 7 , wherein the recombinant PRV polypeptide is a polypeptide encoded by a cDNA that has a nucleic acid sequence substantially identical to the nucleic acid sequence of any of SEQ ID NOs: 1-10.
11 . (canceled)
12 . The PRV polypeptide of claim 7 , wherein the recombinant PRV polypeptide is a polypeptide encoded by a cDNA having a nucleic acid sequence that is at least about 95.5%, about 96%, about 96.5%, about 97%, about 97.5%, about 98%, about 98.5%, about 99%, about 99.5% or about 99.9% identity to a nucleic acid sequence of any one of SEQ ID NOs: 1-10.
13 . The immunogenic composition of claim 7 , wherein the recombinant PRV polypeptide is a polypeptide comprising the amino acid sequence of SEQ ID NOs: 29-40.
14 . (canceled)
15 . The immunogenic composition of claim 7 , wherein the recombinant PRV polypeptide is substantially identical to the amino acid sequence of any of SEQ ID NOs: 29-40.
16 . (canceled)
17 . The recombinant PRV polypeptide of claim 7 , wherein the PRV polypeptide has at least about 95.5%, about 96%, about 96.5%, about 97%, about 97.5%, about 98%, about 98.5%, about 99%, about 99.5% or about 99.9% identity to that of any one of SEQ ID NOs: 29-40.
18 - 24 . (canceled)
25 . An immunogenic composition comprising a killed virus comprising a Piscine Reovirus (PRV) polypeptide.
26 . An immunogenic composition comprising an attenuated virus comprising a Piscine Reovirus (PRV) polypeptide.
27 . The immunogenic composition of claim 7 further comprising at least one excipient, additive or adjuvant.
28 . The immunogenic composition of claim 7 further comprising at least one polypeptide, or fragment thereof, from an additional piscine pathogen.
29 . (canceled)
30 . The immunogenic composition of claim 28 , wherein the additional piscine pathogen is selected from the group consisting of Sleeping disease virus (SDV); salmon pancreas disease virus (SPDV); infectious salmon anemia (ISAV); Viral hemorrhagic septicemia virus (VHSV); infectious hematopoietic necrosis virus (IHNV); infectious pancreatic necrosis virus (IPNV); spring viremia of carp (SVC); channel catfish virus (CCV); Aeromonas salmonicida; Renibacterium salmoninarum; Moritella viscosis, Yersiniosis; Pasteurellosis; Vibro anguillarum; Vibrio logei; Vibrio ordalii; Vibrio salmonicida; Edwardsiella ictaluri; Edwardsiella tarda; Cytophaga columnari ; or Piscirickettsia salmonis.
31 . A method of inducing an immune response in an animal, the method comprising administering the PRV immunogenic composition of claim 7 .
32 . A method for preventing, or reducing PRV infection in an animal, the method comprising administering to the animal the PRV immunogenic composition of claim 7 .
33 . (canceled)
34 . The method of claim 32 , wherein the administration is oral administration, immersion administration or injection administration.
35 .- 36 . (canceled)
37 . A method for preventing, or reducing PRV infection in an animal, the method comprising administering to the animal the isolated PRV immunogenic composition of claim 25 .
38 . A method for preventing, or reducing PRV infection in an animal, the method comprising administering to the animal the PRV immunogenic composition of claim 26 .Join the waitlist — get patent alerts
Track US2016287694A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.